

**Summary of Consolidated Financial Results for the third Quarter of
the Year Ending March 31, 2022 (FY2021)
<Based on Japanese GAAP>**

February 7, 2022

Company name: ASKA Pharmaceutical Holdings Co., Ltd.
 Stock exchange listing: Tokyo
 Stock code: 4886 URL <https://www.aska-pharma-hd.co.jp/english/>
 Representative : President and Representative Director Takashi Yamaguchi
 Inquiries : General Manager Corporate Planning Department Hideaki Kobayashi TEL +81-3-5484-8366
 Scheduled date to file Quarterly Report : February 7, 2022
 Scheduled date to commence dividend payments : -
 Supplementary material for financial results : Yes
 Financial results meeting : No

(Amounts less than one million yen are rounded down)

1. Consolidated financial results for the Third quarter ended December 31, 2021 (from April 1, 2021 to December 31, 2021)

(1) Consolidated operating result Percentages indicate year-on-year changes

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Third quarter of FY2021	44,179	-	4,677	-	4,790	-	4,082	-
Third quarter of FY2020	-	-	-	-	-	-	-	-

Note: Comprehensive income
 Third quarter of FY2021 (Millions of yen) 4,256 (-%)
 Third quarter of FY2020 (Millions of yen) - (-%)

	Earnings per share	Diluted earnings per share
	Yen	Yen
Third quarter of FY2021	143.76	-
Third quarter of FY2020	-	-

Note: There are no financial results for the previous second quarter because ASKA Pharmaceutical Holdings Co., Ltd. was established through a sole share transfer on April 1, 2021.

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio
	Millions of yen	Millions of yen	%
As of December 31, 2021	87,536	48,412	55.3
As of March 31, 2021	-	-	-

Reference: Tangible net worth
 Third quarter of FY2021 (Millions of yen) 48,412
 Third quarter of FY2020 (Millions of yen) -

Note: There are no financial results for the previous year because ASKA Pharmaceutical Holdings Co., Ltd. was established through a sole share transfer on April 1, 2021.

2. Cash dividends

	Annual dividends per share				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2021	-	-	-	-	-
Year ending March 31, 2022	-	7.00	-	-	-
Year ending March 31, 2022 (Forecast)	-	-	-	7.00	14.00

Notes: 1. Revision from the dividend forecast currently announced: No

2. Dividend resources for the second quarter FY2021 are from other capital surplus.

3. There are no financial results for the previous year because ASKA Pharmaceutical Holdings Co., Ltd. was established through a sole share transfer on April 1, 2021.

3. Forecast of consolidated financial results for the year ending March 31, 2022 (from April 1, 2021 to March 31, 2022)

Percentages indicate year-on-year changes

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	55,000	-	3,500	-	3,600	-	3,000	-	105.67

Notes: 1. Revision from the dividend forecast currently announced: No

2. There are no percentage changes from the previous year because ASKA Pharmaceutical Holdings Co., Ltd. was established through a sole share transfer on April 1, 2021.

Notes:

- (1) Changes in significant subsidiaries during the Third quarter of FY2021
(changes in specified subsidiaries resulting from the change in the extent of consolidation): No
- (2) Application of special accounting methods for preparing quarterly consolidated financial statements: No
- (3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements
Changes in accounting policies due to revisions to accounting standards and other regulations: No
Changes in accounting policies due to other reasons: No
Changes in accounting estimates: No
Restatement of prior period financial statements: No

(4) Number of issued shares (common shares)

1) Total number of issued shares at the end of the period (including treasury shares)

As of December 31, 2021	30,563,199	As of March, 2021	-
-------------------------	------------	-------------------	---

2) Number of treasury shares at the end of the period

As of December 31, 2021	2,148,456	As of March, 2021	-
-------------------------	-----------	-------------------	---

3) Average number of shares during the period (cumulative from the beginning of the fiscal year)

Third quarter of FY2021	28,397,461	Third quarter of FY2020	-
-------------------------	------------	-------------------------	---

Note: There are no previous financial results because ASKA Pharmaceutical Holdings Co., Ltd. was established through a sole share transfer on April 1, 2021.

This financial results report is not subject to audit procedures by Certified Public Accountants or audit firm.

Explanation about proper use of the financial forecast figures, and other special notes

- The forecast figures shown in this report are based on information currently available to the Company and may contain certain uncertainties. Actual business results may materially differ from the forecasted figures due to various factors in the future
- ASKA Pharmaceutical Holdings Co., Ltd. was established through a sole share transfer on April 1, 2021 and there are no previous financial results due to our first consolidated fiscal year.

(1) Consolidated Balance Sheets

(Millions of yen)

As of December 31, 2021

Assets	
Current assets	
Cash and deposits	21,369
Notes and accounts receivable - trade, and contract assets	17,061
Merchandise and finished goods	9,461
Work in process	316
Raw materials and supplies	4,636
Other	1,639
Allowance for doubtful accounts	(0)
Total current assets	54,484
Non-current assets	
Property, plant and equipment	11,224
Intangible assets	5,372
Investments and other assets	
Investment securities	11,710
Other	4,761
Allowance for doubtful accounts	(17)
Total investments and other assets	16,454
Total non-current assets	33,052
Total assets	87,536
Liabilities	
Current liabilities	
Notes and accounts payable - trade	5,229
Electronically recorded obligations - operating	3,368
Short-term borrowings	1,943
Other provisions	1,088
Other	7,688
Total current liabilities	19,317
Non-current liabilities	
Long-term borrowings	12,473
Other provisions	258
Retirement benefit liability	6,738
Other	336
Total non-current liabilities	19,806
Total liabilities	39,124
Net assets	
Shareholders' equity	
Share capital	1,197
Capital surplus	694
Retained earnings	46,798
Treasury shares	(3,233)
Total shareholders' equity	45,457
Accumulated other comprehensive income	
Valuation difference on available-for-sale securities	2,886
Foreign currency translation adjustment	89
Remeasurements of defined benefit plans	(21)
Total accumulated other comprehensive income	2,954
Total net assets	48,412
Total liabilities and net assets	87,536

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income
(Consolidated Statements of Income)

(Millions of yen)

	Nine months ended December 31, 2021
Net sales	44,179
Cost of sales	23,485
Gross profit	20,694
Selling, general and administrative expenses	16,017
Operating profit	4,677
Non-operating income	
Interest income	0
Dividend income	251
Other	115
Total non-operating income	367
Non-operating expenses	
Interest expenses	43
Expenses of inactive non-current assets	137
Other	72
Total non-operating expenses	254
Ordinary profit	4,790
Extraordinary income	
Gain on sale of non-current assets	9,425
Total extraordinary income	9,425
Extraordinary losses	
Impairment losses	5,921
Other	2,444
Total extraordinary losses	8,366
Profit before income taxes	5,849
Income taxes - current	1,048
Income taxes - deferred	717
Total income taxes	1,766
Profit	4,082
Profit attributable to owners of parent	4,082

(Consolidated Statements of Income)

(Millions of yen)

	Nine months ended December 31, 2021
Profit	4,082
Other comprehensive income	
Valuation difference on available-for-sale securities	61
Remeasurements of defined benefit plans, net of tax	22
Share of other comprehensive income of entities accounted for using equity method	89
Total other comprehensive income	173
Comprehensive income	4,256
Comprehensive income attributable to	
Comprehensive income attributable to owners of parent	4,256

Supplemental Material

(1) Sales of Main Products

S a l e s o f M a i n P r o d u c t s
(F Y 2 0 2 1 T h i r d Q u a r t e r A c t u a l)

ASKA Pharmaceutical Co., Ltd.

(Millions of yen)

Therapeutic category	Products	FY2020		FY2021		QOQ(%)
		3Q Actual	FY2020 Actual	3Q Actual	FY2021 Forecast	
Antihypertensive agent	CANDESARTAN*	9,603	12,329	9,795	12,056	2.0
Thyroid hormone	THYRADIN	5,572	7,209	5,842	7,326	4.8
GnRH antagonist	RELUMINA	4,365	5,709	5,713	7,643	30.9
LH-RH derivative	LEUPRORELIN	3,629	4,502	3,932	4,844	8.4
Poorly absorbable rifamycin antimicrobial agent	RIFXIMA	3,379	4,334	3,795	4,815	12.3
Dysmenorrhea agent	FREWELL	2,229	2,952	2,643	3,222	18.6
Antithyroid agent	MERCAZOLE	1,084	1,401	1,144	1,434	5.5
Antihypertensive agent	AMLODIPINE	998	1,294	848	1,051	(15.0)
Amyotrophic lateral sclerosis agent	RILUZOLE	870	1,083	758	942	(12.9)
Hyperlipidemic agent	LIPDIL	865	1,096	725	930	(16.1)

*Including compounding agents